Insider Selling: Alignment Healthcare (NASDAQ:ALHC) Insider Sells $201,324.40 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Robert Scavo sold 11,285 shares of the business’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $17.84, for a total transaction of $201,324.40. Following the sale, the insider directly owned 487,685 shares in the company, valued at approximately $8,700,300.40. This represents a 2.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Alignment Healthcare Trading Down 4.5%

Shares of ALHC opened at $17.34 on Friday. Alignment Healthcare, Inc. has a twelve month low of $11.63 and a twelve month high of $23.87. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 1.80. The firm has a market capitalization of $3.54 billion, a P/E ratio of -1,732.27, a PEG ratio of 2.54 and a beta of 1.18. The firm’s 50-day moving average is $20.44 and its two-hundred day moving average is $18.80.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The company’s revenue for the quarter was up 44.4% on a year-over-year basis. During the same period last year, the firm earned ($0.16) EPS. On average, research analysts predict that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current fiscal year.

Trending Headlines about Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Strong fundamentals — Alignment reported Q4 revenue of ~$1.01B and an EPS beat (‑$0.05 vs. consensus ‑$0.15) with revenue up ~44% YoY, which supports longer‑term growth expectations. Earnings Summary
• Positive Sentiment: Analyst bullishness — Multiple brokerages have raised price targets and maintain Buy/Overweight views (e.g., TD Cowen, JPMorgan, KeyCorp, Robert W. Baird), leaving a consensus analyst stance that is constructive for the stock. Analyst Coverage
• Neutral Sentiment: Short‑interest data published for March appears erroneous (shows 0 shares / NaN changes). Do not treat those figures as evidence of new short pressure until exchanges correct the data.
• Neutral Sentiment: High institutional ownership (~86%) can mute volatility from retail flows but also means institutional positioning matters for future moves; a Zacks comparison piece contrasts ALHC with peers for valuation context. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Secondary offering announced by a major shareholder — the planned secondary raises potential near‑term selling supply and is a clear negative for price action until the offering size and timing are known. Alignment Healthcare announces secondary offering by major shareholder
• Negative Sentiment: Clustered insider selling — several senior executives reported sales on Mar 18–19 (CEO John E. Kao: 73,046 shares; President Dawn Maroney: 36,749; COO Sebastian Burzacchi: 15,361; plus multiple other officers, and Robert Scavo sold 11,285). These simultaneous disposals (~tens of thousands of shares each at ~$17.84) create headline risk and likely contributed to today’s negative sentiment. Representative SEC filings: Kao — Kao SEC Filing, Scavo — Scavo SEC Filing

Wall Street Analysts Forecast Growth

A number of analysts have commented on ALHC shares. UBS Group boosted their target price on Alignment Healthcare from $18.00 to $21.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 14th. Wall Street Zen cut Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. JPMorgan Chase & Co. lifted their price target on Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Piper Sandler boosted their price objective on shares of Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 6th. Finally, KeyCorp reissued an “overweight” rating and issued a $28.00 price objective on shares of Alignment Healthcare in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.56.

Institutional Investors Weigh In On Alignment Healthcare

Large investors have recently bought and sold shares of the stock. Wellington Management Group LLP boosted its holdings in shares of Alignment Healthcare by 167.3% during the third quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock worth $193,516,000 after purchasing an additional 6,940,277 shares during the last quarter. Invesco Ltd. lifted its position in Alignment Healthcare by 122.3% during the second quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock worth $58,387,000 after buying an additional 2,294,739 shares during the period. Capital World Investors acquired a new stake in Alignment Healthcare in the 4th quarter worth about $44,203,000. Loomis Sayles & Co. L P acquired a new stake in Alignment Healthcare in the 4th quarter worth about $44,162,000. Finally, Danica Pension Livsforsikringsaktieselskab purchased a new stake in Alignment Healthcare in the 4th quarter valued at about $39,500,000. Institutional investors and hedge funds own 86.19% of the company’s stock.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.